In this workshop, CIRS brought together senior representatives from HTA agencies, pharmaceutical companies, payers and patient organisations to discuss their readiness for the EU HTA Regulation (HTAR) being applied from January 2025. The aim was to make recommendations on how to ensure efficient and effective implementation of the JCA at the national level and to identify metrics that will enable iterative learning among stakeholders.
This one-day workshop consisted of a series of presentation sessions, a panel session and two parallel breakout discussions. The presentations provided agency and industry perspectives on preparations for the HTAR, as well as future considerations for involvement in JCA and national implementation at the Member State level.
The breakout groups were asked to discuss and develop recommendations on two topics:
- Efficiency of the process from JCA to national HTA decision making: Ensuring timely company submissions and efficient agency coordination
- Effectiveness of the JCA: Ensuring the value of JCA outputs to support national HTA decision making
This workshop synopsis summarises key messages and recommendations from the presentations and breakout discussions.
A more in-depth report of the workshop is now available to download here.
